Han Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Han Wei has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Weiyan Cheng
Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
7 shared publications- Xin Tian
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, China
4 shared publications Guanghe Zhu
Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou China
3 shared publicationsJinyan Han
Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou China
3 shared publicationsRuoyang Miao
Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
3 shared publicationsXiaojian Zhang
3 shared publications
Latest Publications
- 22 September 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (9) , e70345
A Photoaffinity Probe for S‑Guanylation Posttranslational Modification to Identify Its Interacting Proteins
S‐guanylation is an endogenous posttranslational modification that has been implicated as a specific autophagic signal, yet its interacting proteins and underlying molecular mechanism remain largely unknown. Here, we developed the first diazirine‐based S‐guanylation photoaffinity probe (SGPP) to capture and identify its interacting proteins in living cells. The SGPP efficiently labeled target proteins in a time‐, concentration‐, and UV‐crosslinking‐dependent manner, as demonstrated by in‐gel fluorescence scanning. Using a chemoproteomic workflow combining SGPP‐mediated photocrosslinking, affinity enrichment, and mass spectrometry, we identified nine candidate binding proteins in HeLa cells, including ACAP2, APOD, DLGAP5, FAM83A, GNB4, LCN1, LSM4, OR5AC2, and RNASEH2A. Orthogonal anti‑GFP pull‑down validation confirmed GNB4 as a bona fide binding partner. Notably, the association of several candidates with guanine nucleotide binding activity validates the reliability of our chemoproteomic identification. To validate the degradation activity of the S‐guanylation warhead and to establish a functionally relevant orthogonal model for validating candidate binding proteins, we established a tetracycline (TetON) inducible expression system, which overcame the limitations of strong constitutive promoters and demonstrated efficient S‐guanylation‐induced degradation of the target protein. Collectively, this study provides the first chemical tool for studying S‐guanylation and identifies GNB4 as a validated binding partner, establishing a foundation for future screening of small molecule drugs that target selective autophagy.
- 22 September 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (9) , e70345
A Photoaffinity Probe for S‑Guanylation Posttranslational Modification to Identify Its Interacting Proteins
S‐guanylation is an endogenous posttranslational modification that has been implicated as a specific autophagic signal, yet its interacting proteins and underlying molecular mechanism remain largely unknown. Here, we developed the first diazirine‐based S‐guanylation photoaffinity probe (SGPP) to capture and identify its interacting proteins in living cells. The SGPP efficiently labeled target proteins in a time‐, concentration‐, and UV‐crosslinking‐dependent manner, as demonstrated by in‐gel fluorescence scanning. Using a chemoproteomic workflow combining SGPP‐mediated photocrosslinking, affinity enrichment, and mass spectrometry, we identified nine candidate binding proteins in HeLa cells, including ACAP2, APOD, DLGAP5, FAM83A, GNB4, LCN1, LSM4, OR5AC2, and RNASEH2A. Orthogonal anti‑GFP pull‑down validation confirmed GNB4 as a bona fide binding partner. Notably, the association of several candidates with guanine nucleotide binding activity validates the reliability of our chemoproteomic identification. To validate the degradation activity of the S‐guanylation warhead and to establish a functionally relevant orthogonal model for validating candidate binding proteins, we established a tetracycline (TetON) inducible expression system, which overcame the limitations of strong constitutive promoters and demonstrated efficient S‐guanylation‐induced degradation of the target protein. Collectively, this study provides the first chemical tool for studying S‐guanylation and identifies GNB4 as a validated binding partner, establishing a foundation for future screening of small molecule drugs that target selective autophagy.
- 24 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (24)
Catalyst‐Free, Divergent Cysteine Modification via Indole Isocyanide Photochemistry
Chemoselective cysteine modification is pivotal for chemical biology and drug discovery. While photochemical strategies offer spatiotemporal control, most current methods rely on exogenous catalysts, complicating purification processes. Furthermore, the structural diversity of accessible conjugates remains limited. Here, we report an additive/catalyst‐free, visible‐light‐driven platform for divergent cysteine modification via indole isocyanide photochemistry. This strategy eliminates the need for external additives or photocatalysts, ensuring excellent biocompatibility and operational simplicity. A key practical advantage of this method is its compatibility with both solution‐phase and solid‐phase reaction systems, offering unmatched flexibility for diverse experimental setups. By leveraging the tunable structure of indole isocyanides, this photoreaction readily generates a diverse array of indole‐fused or indole‐spiro aza‐cycles at cysteine residues. We demonstrate broad utility of this method, ranging from site‐specific modification of peptides and proteins to the synthesis of cyclic peptides and the assembly of proteolysis‐targeting chimeras (PROTACs). Moreover, a chemical proteomics profiling employing indole isocyanide‐based photoprobe achieved selective modification of C77 within the therapeutic phosphatase target PPP5C. This interaction revealed a novel druggable pocket at the TPR–catalytic domain interface, uncovering a previously unknown allosteric inhibition strategy. Collectively, this work establishes a robust, versatile platform for advancing therapeutic discovery and chemical biology.
- 24 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (24)
Catalyst‐Free, Divergent Cysteine Modification via Indole Isocyanide Photochemistry
Chemoselective cysteine modification is pivotal for chemical biology and drug discovery. While photochemical strategies offer spatiotemporal control, most current methods rely on exogenous catalysts, complicating purification processes. Furthermore, the structural diversity of accessible conjugates remains limited. Here, we report an additive/catalyst‐free, visible‐light‐driven platform for divergent cysteine modification via indole isocyanide photochemistry. This strategy eliminates the need for external additives or photocatalysts, ensuring excellent biocompatibility and operational simplicity. A key practical advantage of this method is its compatibility with both solution‐phase and solid‐phase reaction systems, offering unmatched flexibility for diverse experimental setups. By leveraging the tunable structure of indole isocyanides, this photoreaction readily generates a diverse array of indole‐fused or indole‐spiro aza‐cycles at cysteine residues. We demonstrate broad utility of this method, ranging from site‐specific modification of peptides and proteins to the synthesis of cyclic peptides and the assembly of proteolysis‐targeting chimeras (PROTACs). Moreover, a chemical proteomics profiling employing indole isocyanide‐based photoprobe achieved selective modification of C77 within the therapeutic phosphatase target PPP5C. This interaction revealed a novel druggable pocket at the TPR–catalytic domain interface, uncovering a previously unknown allosteric inhibition strategy. Collectively, this work establishes a robust, versatile platform for advancing therapeutic discovery and chemical biology.
- 24 April 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (24) , e24506
Catalyst‐Free, Divergent Cysteine Modification via Indole Isocyanide Photochemistry
Chemoselective cysteine modification is pivotal for chemical biology and drug discovery. While photochemical strategies offer spatiotemporal control, most current methods rely on exogenous catalysts, complicating purification processes. Furthermore, the structural diversity of accessible conjugates remains limited. Here, we report an additive/catalyst‐free, visible‐light‐driven platform for divergent cysteine modification via indole isocyanide photochemistry. This strategy eliminates the need for external additives or photocatalysts, ensuring excellent biocompatibility and operational simplicity. A key practical advantage of this method is its compatibility with both solution‐phase and solid‐phase reaction systems, offering unmatched flexibility for diverse experimental setups. By leveraging the tunable structure of indole isocyanides, this photoreaction readily generates a diverse array of indole‐fused or indole‐spiro aza‐cycles at cysteine residues. We demonstrate broad utility of this method, ranging from site‐specific modification of peptides and proteins to the synthesis of cyclic peptides and the assembly of proteolysis‐targeting chimeras (PROTACs). Moreover, a chemical proteomics profiling employing indole isocyanide‐based photoprobe achieved selective modification of C77 within the therapeutic phosphatase target PPP5C. This interaction revealed a novel druggable pocket at the TPR–catalytic domain interface, uncovering a previously unknown allosteric inhibition strategy. Collectively, this work establishes a robust, versatile platform for advancing therapeutic discovery and chemical biology.
- 24 April 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (24) , e24506
Catalyst‐Free, Divergent Cysteine Modification via Indole Isocyanide Photochemistry
Chemoselective cysteine modification is pivotal for chemical biology and drug discovery. While photochemical strategies offer spatiotemporal control, most current methods rely on exogenous catalysts, complicating purification processes. Furthermore, the structural diversity of accessible conjugates remains limited. Here, we report an additive/catalyst‐free, visible‐light‐driven platform for divergent cysteine modification via indole isocyanide photochemistry. This strategy eliminates the need for external additives or photocatalysts, ensuring excellent biocompatibility and operational simplicity. A key practical advantage of this method is its compatibility with both solution‐phase and solid‐phase reaction systems, offering unmatched flexibility for diverse experimental setups. By leveraging the tunable structure of indole isocyanides, this photoreaction readily generates a diverse array of indole‐fused or indole‐spiro aza‐cycles at cysteine residues. We demonstrate broad utility of this method, ranging from site‐specific modification of peptides and proteins to the synthesis of cyclic peptides and the assembly of proteolysis‐targeting chimeras (PROTACs). Moreover, a chemical proteomics profiling employing indole isocyanide‐based photoprobe achieved selective modification of C77 within the therapeutic phosphatase target PPP5C. This interaction revealed a novel druggable pocket at the TPR–catalytic domain interface, uncovering a previously unknown allosteric inhibition strategy. Collectively, this work establishes a robust, versatile platform for advancing therapeutic discovery and chemical biology.
- 7 March 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 134, 106457
Chemoproteomics reveals arctigenin as a phagophore-closure blocker via targeting ESCRT-I subunit VPS28
- 7 March 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 134, 106457
Chemoproteomics reveals arctigenin as a phagophore-closure blocker via targeting ESCRT-I subunit VPS28
- 1 October 2020
- Published by Elsevier in Sensors and Actuators B: Chemical
- Vol. 321
Vimentin-targeting AIEgen-peptide conjugates: Wash-free fluorescence detection of EMT-type cancer cells and tissues
- 1 October 2020
- Published by Elsevier in Sensors and Actuators B: Chemical
- Vol. 321
Vimentin-targeting AIEgen-peptide conjugates: Wash-free fluorescence detection of EMT-type cancer cells and tissues
- 1 November 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 182, 111615
An overview of recent progress in siderophore-antibiotic conjugates
- 1 November 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 182, 111615
An overview of recent progress in siderophore-antibiotic conjugates
- 1 February 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 164, 615-639
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
- 1 February 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 164, 615-639
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
- 6 December 2018
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 10 (23) , 2729-2744
Smart Fluorescent Probes for In Situ Imaging of Enzyme Activity: Design Strategies and Applications
Enzymes play critical roles in the physiological and pathological processes of living systems. To provide detailed pictures of enzyme activity at the molecular and cellular levels, interdisciplinary studies of chemistry and biology have led to the emergence of many smart fluorescent probes, which emit fluorescence or show a shifted signal only upon interaction with their targets. With distinct advantage of a higher signal-to-noise ratio than traditional ‘always on’ probes, smart fluorescent probes enable sensitive detection of enzymes with clinical significance. In this review, we summarize the design strategies and selected applications of smart fluorescent probes for in situ imaging of enzyme activity. Current challenges and future developments in this field are also discussed.
- 6 December 2018
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 10 (23) , 2729-2744
Smart Fluorescent Probes for In Situ Imaging of Enzyme Activity: Design Strategies and Applications
Enzymes play critical roles in the physiological and pathological processes of living systems. To provide detailed pictures of enzyme activity at the molecular and cellular levels, interdisciplinary studies of chemistry and biology have led to the emergence of many smart fluorescent probes, which emit fluorescence or show a shifted signal only upon interaction with their targets. With distinct advantage of a higher signal-to-noise ratio than traditional ‘always on’ probes, smart fluorescent probes enable sensitive detection of enzymes with clinical significance. In this review, we summarize the design strategies and selected applications of smart fluorescent probes for in situ imaging of enzyme activity. Current challenges and future developments in this field are also discussed.
- 1 November 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 131, 444-453
Pharmaceutical applications of affinity-ultrafiltration mass spectrometry: Recent advances and future prospects
- 1 November 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 131, 444-453
Pharmaceutical applications of affinity-ultrafiltration mass spectrometry: Recent advances and future prospects